Vistogard

Added: Oct 16, 2017 6:17 pm Chapter VI: Other Than Full and Open Competition (OFOC) SOP

Attachment 4: Single Source Justification for SAP under $150K



OFOC SOP Revision 05 Page 1 of 1

Original Date: 03/22/11

Revision 05 Date: 05/02/2016

JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1

(OVER MICRO-PURCHASE THRESHOLD($3.5K) BUT NOT EXCEEDING THE SAT ($150K))

IAW FAR13.104, COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW FAR13.106-1(b), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW FAR13.106-3(b)(3),COs are required to include additional statements explaining the absence of competition (see 13.106-1 for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW FAR13.106-3(b)(3). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

ACQUISITION PLAN ACTION ID:

VA261-17-AP-15412

1A. PROJECT/TASK No.

1B. ESTIMATED AMOUNT:



XXXXXXXXX

2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE:

Emergency requirement for the drug Vistogard to rapidly treat chemotherapy overdose.





3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:

Only the drug Vistogard would meet the patient s needs. While there are multiple distributors, Vistogard was sought directly from Cardinal Health in an urgent effort to save the patient s life. The drug has been ordered, delivered, and administered to the patient.







4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:

Market research consisted of searches of Google, VA NAC catalog search tool, and FPDS. Vistogard was approved by the FDA in 2015 to treat emergency acute chemotherapy overdose. Nationwide, VA has purchased the drug from Cardinal Health 3 times since.